Where innovative Medical Go-To-Market Success is the rule! 

Want to Learn or See More? Click here

Synergistic Marketing, founded in 1990 by Mark Lutvak, is a successful, growing and profitable sales and marketing contracting firm and consultancy. We are dedicated to serving Small Emerging businesses that own or possess Medical Technology or Medical Device IP. We support our clients with a go-to-market strategy that takes advantage of our extensive network of medical industry companies as well as our extensive list of contacts who are our Corporate Partners.

Want to Learn or See More? Click here

 

Medical Technology and Device News Title

  • May 28, 2019:

    The FDA has issued Stryker with approval for the company’s Neuroform Atlas Stent System. It is indicated for treatment of wide-neck, intracranial aneurysms in conjunction with embolic detachable coils, so far only the second stent approved for such procedures. The nitinol Neuroform Atlas stent is used to hold tiny metal coils inside an aneurysm, working together with the coils at preventing further expansion of the aneurysm.Full Story

  • May 21, 2019:

    Abiomed, the maker of left ventricular assist devices, is releasing its newly FDA approved Impella CP with SmartAssist device. The pump features an optical sensor that physicians can use to position and reposition the device without relying on a cath lab, X-ray, or ultrasound imaging. This next generation heart pump is designed to improve patient outcomes by using real-time intelligence to optimize positioning, managing and weaning of the Impella device for better patient care. Full Story

  • May 18, 2019:

    Researchers at the University of Georgia have developed a microfluidic chip to isolate circulating tumor cells (CTCs) from blood samples. CTCs could allow clinicians to diagnose cancer. Unlike other devices, this new chip uses magnetic microbeads to strip all the cells from the blood, leaving only the CTCs, in a technique the researchers have called “integrated ferrohydrodynamic cell separation”. The device is highly efficient and isolates almost all the CTCs in a blood sample (over 99%).Full Story

  • May 11, 2019:

    Scientists at the Howard Hughes Medical Institute have achieved a world’s first of beating a bacterial infection using an engineered virus. A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement, including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules.Full Story

  • May 9, 2019:

    Researchers from Northwestern University have published a paper in Nature Biomedical Engineering about leveraging machine learning to aid in the design of nanomedicines for immunotherapy. They utilized a high-throughput method to synthesize 800 unique immunostimulatory nanoparticles called Spherical Nucleic Acids (SNAs). The team synthesized these particles by varying across 11 different design parameters, including particle size, composition, and the specific immunostimulant being carried. “Spherical nucleic acids represent an exciting new class of medicines that are already in five human clinical trials for treating diseases said Northwestern professor Chad A. Mirkin, the inventor of SNAs.Full Story